Trial Profile

Randomized phase III study of S-1 based chemotherapy plus nivolumab versus S-1 based chemotherapy alone for patients with locally advanced/borderline resectable pancreatic cancer (Investigator initiated trial)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Pancreatic cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms PENETRATE

02 Nov 2024 Trial design published in the Japanese Journal of Clinical Oncology.
24 Dec 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com